The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 82)
Improved Biomarkers and Clinical Outcome Measures, 2016
There is a great need to identify Parkinson's disease (PD) in its earliest stages when interventions may prevent or slow neural degeneration. Given that the earliest brain pathology of PD occurs outside of the motor system, namely in the olfactory bulbs (brain regions that detect smell) and the brainstem (brain region that controls involuntary functions), we are probing the functi...
Pre-Clinical Alpha-Synuclein Models, 2016
One of the hallmarks of Parkinson's disease (PD) is the presence and aggregation (clumping) of a misfolded protein called alpha-synuclein; however, we do not know how this misfolding happens. In 2003, Braak and colleagues suggested that alpha-synuclein pathology was "transmissible" (contagious). Additionally, studies have shown that normal dopamine neurons transplanted into Parkins...
Researchers: Richard Jay Smeyne, PhD
Therapeutic Pipeline Program, 2015
Gait and balance disorders are the primary motor disability in advanced Parkinson's disease (PD). These disorders arise in part due to dysfunction of the lateral mesencephalus [part of the brainstem] and one of its nuclei, the pedunculopontine nucleus (PPN). Deep brain stimulation (DBS) of the PPN area has been used to alleviate gait disorders, and while the init...
Research Grant, 2014
Many of the motor symptoms in Parkinson's disease (PD) are attributed to a deficit of the neurotransmitter dopamine in the brain region called the striatum. Recent studies show that mutations in the gene LRRK2 underlie familial PD, and that the protein LRRK2 modulates dopamine in the striatum. We plan to determine how LRRK2 affects dopamine release and whether it controls the ...
Researchers: Austen James Milnerwood, PhD
Rapid Response Innovation Awards, 2014
Parkinson's disease is characterized by the loss of a neurotransmitter called dopamine in a part of the brain called the basal ganglia. Parts of this region are responsible for the control of habits and skills, and new evidence shows that dopamine loss begins in these areas. Our work studying errors in skilled movements has focused on typing. We are particular in...